Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management

Fineline Cube Jul 16, 2026
Company Drug

Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Partners with Sino Biopharmaceutical for First-in-Class Monoclonal Antibody Development

Fineline Cube Dec 30, 2024

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...

Policy / Regulatory

Hainan Free Trade Port Gets Green Light for Temporary Import of Special Medical Foods

Fineline Cube Dec 30, 2024

The State Administration for Market Regulation (SAMR) in China has given its approval in principle...

Company

GenFleet Therapeutics Submits IPO Application to HKEX, Backed by CITIC Securities

Fineline Cube Dec 29, 2024

On December 27, 2024, GenFleet Therapeutics, a biopharmaceutical company based in Shanghai, submitted its application...

Company

Overwhelming Shareholder Support for Hengrui Pharmaceuticals’ H-Share IPO

Fineline Cube Dec 29, 2024

On December 26, Hengrui Pharmaceuticals (SHA: 600276) held its second extraordinary general meeting of 2024,...

Company

Dynamiker Biotechnology Receives Approval for IPO on Beijing Stock Exchange

Fineline Cube Dec 28, 2024

On December 27, 2024, the official website of the Beijing Stock Exchange announced that Dynamiker...

Company

MicroPort Endovascular MedTech’s Castor® Branched Stent Wins China Patent Gold Award

Fineline Cube Dec 28, 2024

The National Intellectual Property Administration has announced the winners of the 25th China Patent Awards,...

Company Drug

Daiichi Sankyo and AstraZeneca Withdraw EU Application for Datopotamab Deruxtecan in Lung Cancer

Fineline Cube Dec 27, 2024

Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced the voluntary...

Company

AstraZeneca China Announces Structural Adjustments to Oncology Business Divisions

Fineline Cube Dec 27, 2024

UK major AstraZeneca’s (AZ, NASDAQ: AZN) China unit has announced a new round of structural...

Company Drug Hospital Medical Device Policy / Regulatory

Beijing Releases List of Novel Drugs and Technologies Exempt from CHS-DRG Payment Scheme

Fineline Cube Dec 27, 2024

The Beijing Municipal Medical Insurance Bureau has released the list of the first batch of...

Company Deals Drug

Johnson & Johnson Secures Licensing Deal with Kaken Pharmaceutical for STAT6 Program

Fineline Cube Dec 27, 2024

US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced an exclusive licensing agreement with...

Company Deals

Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach

Fineline Cube Dec 27, 2024

China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to...

Company Drug

Auzone Submits NDA for Oral Edaravone TTYP01 to Treat ALS

Fineline Cube Dec 27, 2024

Auzone Biological Technology has announced the submission of a New Drug Application (NDA) for its...

Company Drug

Pediatrix Therapeutics’ Neffy NDA Accepted by NMPA for Allergy Treatment

Fineline Cube Dec 27, 2024

China-based Pediatrix Therapeutics has announced that the New Drug Application (NDA) for its neffy (epinephrine...

Company Deals

Immunochina Pharmaceuticals and Cell Store Partner to Advance Cell Therapy Commercialization in China

Fineline Cube Dec 27, 2024

Beijing-based firms Immunochina Pharmaceuticals and Cell Store have announced a strategic partnership aimed at bolstering...

Company Drug

Hinova Pharmaceuticals Enrolls First Patient in Phase II Study for HP518 in mCRPC

Fineline Cube Dec 27, 2024

China-based biopharma Hinova Pharmaceuticals has announced the enrollment of the first patient in an open,...

Company Deals

Xbiome Partners with ZoHealth to Advance Microbiome Drug Development and Precision Nutrition

Fineline Cube Dec 27, 2024

China-based Xbiome, an AI-driven microbiome drug development company, has announced a strategic alliance with Australia-headquartered...

Company Deals Drug

Astellas Pharma Partners with Axcelead DDP for Targeted Protein Degraders Discovery

Fineline Cube Dec 27, 2024

Japan-based Astellas Pharma Inc. (TYO: 4503) has struck an accord with compatriot firm Axcelead Drug...

Company Deals

AusperBio Secures $73 Million in Series B Financing to Advance Hepatitis B Therapy

Fineline Cube Dec 27, 2024

Sino-US liver therapy developer AusperBio has announced the completion of a USD 73 million Series...

Company Drug

Advaccine Biotechnology’s MICROEPAD Receives FDA Registration Approval

Fineline Cube Dec 27, 2024

China-based vaccine developer Advaccine Biotechnology has announced receiving registration approval from the US Food and...

Company Deals

Shandong Buchang Pharmaceuticals Terminates Agreement with NOVAST Laboratories

Fineline Cube Dec 27, 2024

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced the termination of the development,...

Posts pagination

1 … 267 268 269 … 695

Recent updates

  • Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management
  • Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus
  • Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset
  • WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028
  • China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Lepu Medical Secures NMPA Clinical Trial Approval for MWN110, Novel ActRIIA/B Antibody for Weight Management

Company Drug

Merck KGaA’s Enpatoran Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.